tixagevimab-cilgavimab
Selected indexed studies
- Tixagevimab + Cilgavimab: First Approval. (Drugs, 2022) [PMID:35727563]
- Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review. (Expert Rev Anti Infect Ther, 2022) [PMID:36217836]
- Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience. (Viruses, 2022) [PMID:36680160]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tixagevimab + Cilgavimab: First Approval. (2022) pubmed
- Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review. (2022) pubmed
- Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience. (2022) pubmed
- Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. (2023) pubmed
- Tixagevimab-cilgavimab for preventing breakthrough COVID-19 in dialysis patients: a prospective study. (2024) pubmed
- Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. (2022) pubmed
- Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak. (2023) pubmed
- Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants? (2024) pubmed
- Tixagevimab-Cilgavimab Decreases the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients. (2023) pubmed
- The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis. (2024) pubmed